OmniRx lists retatrutide peptide products for research-use only (RUO). Each listing includes full product data — CoA, HPLC purity, and MS confirmation — and directs researchers to verified purchase options.
For research purposes only. Not intended for human therapeutic use. See full disclaimer below.
Published in the New England Journal of Medicine (2023), Phase 2 TRIUMPH data positions retatrutide as the most potent weight-reducing peptide investigated to date.
Retatrutide (development code LY3437943, CAS 2381089-83-2) is a 39-amino acid synthetic peptide engineered as a triple receptor agonist — simultaneously activating GLP-1, GIP, and glucagon receptors. This three-pronged mechanism produces coordinated metabolic effects that exceed the weight-reducing capacity of earlier single- and dual-agonist peptides.
Developed by Eli Lilly, retatrutide advanced through Phase 2 trials with results published in the New England Journal of Medicine in June 2023. The TRIUMPH Phase 3 program began enrollment in 2023 and is currently ongoing. It is not yet FDA-approved for any therapeutic use and is listed by OmniRx for research-use only (RUO).
RUO Disclaimer: Retatrutide is sold strictly for in vitro and laboratory research purposes. It is not approved by the FDA for human therapeutic use, is not a drug or medicine, and must not be used for self-administration or clinical treatment. OmniRx makes no therapeutic claims regarding this compound.
Research integrity starts with compound quality. Every retatrutide listing on OmniRx includes comprehensive documentation so your research begins on solid ground.
Every batch includes a full certificate of analysis (CoA), HPLC chromatogram, and mass spectrometry (MS) confirmation.
Orders ship with proper cold-chain packaging to preserve peptide integrity throughout transit.
≥98% purity standard on all retatrutide listings. Full product documentation available for research compliance.
Sequence, MW, CAS number, and reconstitution guidance provided with every listing to support your research workflow.
How retatrutide's triple-agonist mechanism compares to existing GLP-1 class agents.
| Feature | Semaglutide | Tirzepatide | Retatrutide (RUO) |
|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Peak trial weight loss | ~15% (68 wks) | ~22% (72 wks) | ~24.2% (48 wks)* |
| Metabolic rate boost | Modest | Moderate | Enhanced (glucagon) |
| Hepatic fat reduction | Moderate | Moderate–High | ~58% in sub-analyses* |
| FDA approval status | Yes (Ozempic/Wegovy) | Yes (Mounjaro/Zepbound) | Not yet — Phase 3 |
| OmniRx listing type | Prescription | Prescription | Research-Use Only |
| * Phase 2 data (NEJM 2023). Retatrutide is not FDA-approved. Listed for research use only. | |||
Common questions from researchers about retatrutide peptide, its mechanism, and how to order it online.
Take the quick assessment to see if retatrutide is right for you, or go ahead and place your order now. Every order includes CoA, HPLC purity report, and MS confirmation.
Retatrutide is listed for research-use only (RUO). It is not a drug, not FDA-approved for human therapeutic use, and is not sold for self-administration. By purchasing, you confirm that you are acquiring this compound for legitimate laboratory research purposes.